MAPK9 and breast carcinoma: Analysis of mammary carcinoma-free survival of Trp53−/+ mice, Jnk1−/− Trp53−/+ mice, and Jnk2−/− Trp53−/+ mice demonstrated that JNK1-deficiency (p = 0.018) and JNK2-deficiency (p = 0.039) significantly decreased survival compared with control Trp53−/+ mice (Figure 5C).